Ionetix to provide Bayer with Therapeutic Radioisotope Actinium-225 (Ac-225)
“We recognized the emerging demand and made the early investment to develop a commercial-scale production solution for Ac-225 using our expertise in cyclotron accelerator and target technology,” said David Eve, VP of Medical Affairs for Ionetix Corporation. Located in Lansing, Michigan, Ionetix has established a new isotope production facility that is dedicated to manufacturing alpha-emitters. The first cyclotron was commissioned at the facility earlier this year and installation of a second cyclotron is planned for 2024. Both cyclotrons will be used to produce alpha-emitters, providing both onsite redundancy and increased capacity to scale output. Distribution of GMP grade, n.c.a. Ac-225 will begin in early 2024.
Share:
More News
Lamine Mbow, Global Head of Discovery Research, Boehringer Ingelheim, said: “We are building a broad pipeline of ADCs addressing novel tumor target space to develop next-generation cancer treatments. By combining our deep expertise in cancer treatment development with Synaffix’s clinical-stage platform technology, we aim to accelerate the delivery of first-in-class
“The initial therapy of high-risk, non-muscle invasive bladder cancer with BCG has not advanced in decades. Today’s pivotal Phase 3 CREST results are potentially practice-changing, representing the first advance in therapy for BCG-naïve, high-risk, non-muscle invasive cancer in over 30 years,” said Roger Dansey, M.D., Chief Oncology Officer, Pfizer. “These
“Receiving FDA IND clearance is an important milestone in the advancement of TYRA-300 and for patients with NMIBC who urgently need better tolerated therapeutic options,” commented Doug Warner, Chief Medical Officer of TYRA. “We look forward to leveraging Erik’s impressive background to guide our development plans in NMIBC. We expect
“As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations,” said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. “We look forward to partnering with Simcere Zaiming, to advance
